Applicant: Růdi D. NEIRINCKX Application No. 09/584,978 Attorney Docket No. 2502491-991110 (formerly 44334)

IN THE SPECIFICATION:

Page 1, after the second paragraph, kindly delete the two newly introduced paragraphs of the prior Amendment and insert the following:

The invention relates to methods for delivering, for example, EGF to a psoriatic site. Topical formulations or systemic administration can be used. The amount of EGF can range from 0.01 to 50 ug/g. The composition can contain 0.5-20 ug/g of EGF. The formulation also can contain other ingredients, such as an anti-inflammatory. The formulation can contain sulfadiazine. The amount of sulfadiazine can range from 0.1 to 3% (w/w) and the amount of EGF can range from 0.5-20 ug/g. For example, a formulation can contain 1% sulfadiazine and 10 ug of EGF.

EGF precursors, such as FGF, or molecules with similar function, such as urogastrone or EGF truncations can be used.